INSM · INSMED Inc
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-10 | Adsett Roger |
Chief Operating Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. |
Common Stock
|
82,280 |
| 2026-08-10 | Adsett Roger |
Chief Operating Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
80,970 |
| 2026-08-10 | Adsett Roger |
Chief Operating Officer |
Convert↑
|
Common Stock
|
80,970 |
| 2026-08-10 | Adsett Roger |
Chief Operating Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
76,600 |
| 2026-08-10 | Adsett Roger |
Chief Operating Officer |
Convert↑
|
Common Stock
|
76,600 |
| 2026-08-10 | Adsett Roger |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This is the weighted average sales price representing 239,850 shares sold at prices ranging from $133.00 to $133.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
239,850 |
| 2026-08-10 | Adsett Roger |
Chief Operating Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
82,280 |
| 2026-08-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
8,895 |
| 2026-08-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the Initial Vesting Date. |
Stock Option (right to buy)
|
8,895 |
| 2026-08-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
18,278 |
| 2026-08-06 | Flammer Martina M.D. |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
8,895 |
| 2026-08-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
18,278 |
| 2026-08-06 | Flammer Martina M.D. |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 18,278 shares sold at prices ranging from $129.40 to $129.41 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
18,278 |
| 2026-07-23 | Lewis William |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
6,260 |
| 2026-07-23 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
5,872 |
| 2026-07-23 | Lewis William |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
4,440 |
| 2026-07-23 | Lewis William |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
6,260 |
| 2026-07-23 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
4,828 |
| 2026-07-23 | Lewis William |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
4,440 |
| 2026-07-09 | Lewis William |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
6,259 |
| 2026-07-09 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 5,005 shares sold at prices ranging from $116.01 to $117.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
5,005 |
| 2026-07-09 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 2,335 shares sold at prices ranging from $117.05 to $117.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
2,335 |
| 2026-07-09 | Lewis William |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. |
Common Stock
|
6,259 |
| 2026-07-09 | Lewis William |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
4,440 |
| 2026-07-09 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 3,359 shares sold at prices ranging from $118.06 to $118.80 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
3,359 |
| 2026-07-09 | Lewis William |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
4,440 |
| 2026-07-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
7,945 |
| 2026-07-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
7,945 |
| 2026-07-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
4,357 |
| 2026-07-06 | Flammer Martina M.D. |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 7,448 shares sold at prices ranging from $110.36 to $110.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
7,448 |
| 2026-07-06 | Flammer Martina M.D. |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
4,357 |
| 2026-07-06 | Flammer Martina M.D. |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 4,854 shares sold at prices ranging from $108.90 to $109.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
4,854 |
| 2026-06-25 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 1,836 shares sold at prices ranging from $102.78 to $103.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
1,836 |
| 2026-06-25 | Lewis William |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
12,518 |
| 2026-06-25 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 2,456 shares sold at prices ranging from $104.90 to $105.88 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
2,456 |
| 2026-06-25 | Lewis William |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Stock Option (right to buy)
|
8,880 |
| 2026-06-25 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 12,091 shares sold at prices ranging from $101.78 to $102.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
12,091 |
| 2026-06-25 | Lewis William |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
12,518 |
| 2026-06-25 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 3,723 shares sold at prices ranging from $103.87 to $104.75 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
3,723 |
| 2026-06-25 | Lewis William |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
8,880 |
| 2026-06-25 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 1,292 shares sold at prices ranging from $105.90 to $106.45 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
Common Stock
|
1,292 |
| 2026-06-23 | Butera Samuele |
SVP, GM, Global Respiratory |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. |
Stock Option (right to buy)
|
12,570 |
| 2026-06-23 | Butera Samuele |
SVP, GM, Global Respiratory |
Award↑
Filing footnotes — Common Stock (Direct)
Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. Each RSU was granted on June 23, 2026, for no consideration. |
Common Stock
|
7,342 |
| 2026-06-23 | Butera Samuele |
SVP, GM, Global Respiratory |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-22 | Smith Michael Alexander |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
1,806 |
| 2026-06-08 | Lewis William |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
6,515 |
| 2026-06-05 | Flammer Martina M.D. |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
Common Stock
|
1,858 |
| 2026-06-03 | Adsett Roger |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. |
Common Stock
|
2,370 |
| 2026-06-03 | Bonstein Sara |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. |
Common Stock
|
2,404 |
| 2026-06-03 | Smith Michael Alexander |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. |
Common Stock
|
2,159 |